{{Drugbox
| drug_name = Tofogliflozin monohydrate
| IUPAC_name = (1''S'',3<nowiki>'</nowiki>''R'',4<nowiki>'</nowiki>''S'',5<nowiki>'</nowiki>''S'',6<nowiki>'</nowiki>''R'')-6-(4-Ethylbenzyl)-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3''H''-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol hydrate (1:1)
| image = Tofogliflozin monohydrate skeletal 3D.svg
| alt =
| caption =

<!-- Clinical data -->
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Investigational
| routes_of_administration =

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!-- Identifiers -->
| CAS_number = 1201913-82-7
| CAS_supplemental  = <br/>{{CAS|903565-83-3}} ([[anhydrous]])
| ATCvet =
| ATC_prefix = None
| ATC_suffix =
| PubChem = 46908928
| DrugBank =
| ChemSpiderID = 28527871
| ChEMBL = 2105711
| KEGG = D09978
| synonyms = CSG452

<!-- Chemical data -->
| C = 22 | H = 28 | O = 7
| molecular_weight  = 404.45 g/mol
| smiles = CCc1ccc(cc1)Cc2ccc3c(c2)[C@]4([C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC3.O
| StdInChI = 1S/C22H26O6.H2O/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22;/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3;1H2/t18-,19-,20+,21-,22+;/m1./s1
| StdInChIKey = ZXOCGDDVNPDRIW-NHFZGCSJSA-N
}}

'''Tofogliflozin''' ([[International nonproprietary name|INN]],<ref name="INN">{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65|url=http://www.who.int/entity/medicines/publications/druginformation/innlists/RL65.pdf|publisher=World Health Organization|accessdate=15 November 2016}}</ref>{{rp|88}} [[United States Adopted Name|USAN]], codenamed '''CSG452''') is an experimental drug for the treatment of [[diabetes mellitus]] and is being developed by [[Chugai Pharma]] in collaboration with [[Kowa Co.|Kowa]] and [[Sanofi]].<ref>[http://www.chugai-pharm.co.jp/hc/ss/english/ir/reports_downloads/pipeline.html Chugai Pharmaceutical: Development Pipeline]</ref> It is an inhibitor of subtype 2 [[sodium-glucose transport protein]] ([[SGLT2]]), which is responsible for at least 90% of the glucose [[reabsorption]] in the kidney. {{as of|2012|9}}, the drug is in Phase III [[clinical trial]]s.<ref>{{Cite journal 
| last1 = Nagata | first1 = T. 
| last2 = Fukazawa | first2 = M. 
| last3 = Honda | first3 = K. 
| last4 = Yata | first4 = T. 
| last5 = Kawai | first5 = M. 
| last6 = Yamane | first6 = M. 
| last7 = Murao | first7 = N. 
| last8 = Yamaguchi | first8 = K. 
| last9 = Kato | first9 = M. 
| doi = 10.1152/ajpendo.00545.2012 
| last10 = Mitsui | first10 = T. 
| last11 = Suzuki | first11 = Y. 
| last12 = Ikeda | first12 = S. 
| last13 = Kawabe | first13 = Y. 
| title = Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats 
| journal = AJP: Endocrinology and Metabolism 
| volume = 304 
| issue = 4 
| pages = E414–E423 
| year = 2012 
| pmid = 23249697 
| pmc = 
}}</ref><ref>{{Cite journal 
| last1 = Ohtake | first1 = Y. 
| last2 = Sato | first2 = T. 
| last3 = Kobayashi | first3 = T. 
| last4 = Nishimoto | first4 = M. 
| last5 = Taka | first5 = N. 
| last6 = Takano | first6 = K. 
| last7 = Yamamoto | first7 = K. 
| last8 = Ohmori | first8 = M. 
| last9 = Yamaguchi | first9 = M. 
| doi = 10.1021/jm300884k 
| last10 = Takami | first10 = K. 
| last11 = Yeu | first11 = S. Y. 
| last12 = Ahn | first12 = K. H. 
| last13 = Matsuoka | first13 = H. 
| last14 = Morikawa | first14 = K. 
| last15 = Suzuki | first15 = M. 
| last16 = Hagita | first16 = H. 
| last17 = Ozawa | first17 = K. 
| last18 = Yamaguchi | first18 = K. 
| last19 = Kato | first19 = M. 
| last20 = Ikeda | first20 = S. 
| title = Discovery of Tofogliflozin, a NovelC-Arylglucoside with anO-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes 
| journal = Journal of Medicinal Chemistry 
| volume = 55 
| issue = 17 
| pages = 7828–7840 
| year = 2012 
| pmid = 22889351 
| pmc = 
}}</ref>

==Chemistry==
[[File:Tofogliflozin skeletal 3D.svg|thumb|left|Anhydrous tofogliflozin]]{{clear left}}
The active moiety or [[anhydrous]] form ([[ChemSpider]] ID: [http://www.chemspider.com/Chemical-Structure.28530778.html 28530778], [[CHEMBL]][https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110731 2110731]) has the chemical formula C<sub>22</sub>H<sub>26</sub>O<sub>6</sub> and a [[molecular mass]] of 386.44&nbsp;g/mol.

The [[United States Adopted Name]] ''tofogliflozin'' applies to the [[monohydrate]], which is the form used as a drug.<ref>[http://www.ama-assn.org/resources/doc/usan/tofogliflozin.pdf Statement on a nonproprietary name adopted by the USAN council: Tofogliflozin].</ref> The [[International Nonproprietary Name]] ''tofogliflozin'' applies to the anhydrous compound<ref name="INN" /> and the drug form is referred to as ''tofogliflozin hydrate''.

==See also==
* [[Gliflozin]]

==References==
{{reflist}}

{{Oral hypoglycemics and insulin analogs}}

[[Category:SGLT2 inhibitors]]
[[Category:Glucosides]]
[[Category:Spiro compounds]]

{{gastrointestinal-drug-stub}}